Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) EPS (Basic) (2017 - 2024)

Solid Biosciences' EPS (Basic) history spans 8 years, with the latest figure at -$1.02 for Q4 2024.

  • For Q4 2024, EPS (Basic) fell 2.0% year-over-year to -$1.02; the TTM value through Dec 2024 reached -$3.06, up 36.78%, while the annual FY2024 figure was -$3.06, 36.65% up from the prior year.
  • EPS (Basic) for Q4 2024 was -$1.02 at Solid Biosciences, down from -$0.79 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.16 in Q2 2021 and bottomed at -$24.11 in Q4 2020.
  • The 5-year median for EPS (Basic) is -$1.01 (2023), against an average of -$2.68.
  • The largest annual shift saw EPS (Basic) crashed 3498.51% in 2020 before it soared 90.66% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at -$24.11 in 2020, then skyrocketed by 69.35% to -$7.39 in 2021, then skyrocketed by 90.66% to -$0.69 in 2022, then tumbled by 44.93% to -$1.0 in 2023, then decreased by 2.0% to -$1.02 in 2024.
  • Per Business Quant, the three most recent readings for SLDB's EPS (Basic) are -$1.02 (Q4 2024), -$0.79 (Q3 2024), and -$0.61 (Q2 2024).